ScholarWorks@중앙대학교

초록

Conventional chemotherapy is often limited by off-target effects and drug resistance, which lead to suboptimal therapeutic efficacy. To address these challenges, we developed a CXCR4-binding peptide-functionalized core/ shell nanocarrier composed of M1 macrophage-derived vesicles coated with micelles loaded with 6-bromoindirubin-3 '-oxime (6BIO). This core/shell nanocarrier employed surface engineering to enhance the targeting of CXCR4-overexpressing cancer cells. Functionalization with CXCR4-binding peptides significantly improved surface interactions, resulting in enhanced cellular uptake and localized drug release in cancer cells. Surface- modified core/shell nanocarriers not only enhance chemotherapeutic efficacy but also boost immunotherapeutic responses and improve overall therapeutic outcomes. Following hybrid vesicle coating on micelles, colorectal carcinoma cell migration was significantly inhibited, and cytotoxicity against colorectal carcinoma cells markedly increased. In vitro studies confirmed the synergistic effects of 6BIO-mediated chemotherapy and macrophage vesicle-driven immunotherapy, establishing a novel platform for highly specific combination cancer therapies.

키워드